Latest news with #STS
New Straits Times
11-07-2025
- Politics
- New Straits Times
New rules to curb illegal ship-to-ship oil transfers in Malaysian waters
KUALA LUMPUR: Malaysia is set to enforce new regulations targeting illegal ship-to-ship (STS) transfers of oil in its waters starting this month. Foreign Minister Datuk Seri Mohamad Hasan said the decision aimed to strengthen enforcement and address concerns over illicit activities within the country's maritime zones. He said the long-standing issue of STS operations had been a "thorn in the side" for Malaysia, with the country often accused by certain parties of facilitating questionable oil transfers, including those involving sanctioned entities. "We have been accused by some quarters of enabling such activities, particularly involving oil, and operating in contested waters. "While we maintain these areas fall under our jurisdiction, the perception differs. "That's why we are going to start enforcing the rules. "In the past, any attempt to do so was met with criticism, but now we have no choice," he said at a press conference following the 58th Asean Foreign Ministers' Meeting (AMM) here today. He said that once the regulations are in place, strict enforcement will follow, including fines or the detention of vessels found in breach. "If anyone is caught conducting unauthorised STS transfers, we will detain the vessel and take legal action. "Fines will be imposed, or the ships will be impounded." Malaysia has been under scrutiny over allegations that its waters have been used as a convenient zone for transferring oil between vessels, often involving unclear origins or destinations, and sometimes linked to sanctions evasion. "We no longer want to be accused of allowing or facilitating such activities. "It's frustrating when we request proper coordinates from foreign parties and they turn out to be outside our jurisdiction." Mohamad said Malaysia would increase surveillance and maritime enforcement to ensure all STS activity is monitored and controlled. "If we detect any suspicious STS operations, we will act. "Enforcement will begin in July, a Cabinet decision has already been made. "Yes, some may be unhappy, but we cannot allow Malaysia to be painted as a safe haven for illegal oil transfers." On May 9 last year, the United States expressed concern that waters off Malaysia and elsewhere in the region were being used as transit points for Iranian oil sales aimed at evading US sanctions. US Treasury Under Secretary for Terrorism and Financial Intelligence Brian Nelson said Washington had been closely monitoring STS transfers in Malaysian waters, particularly those suspected to be linked to sanctioned Iranian entities. On Feb 24, a Labuan-based company was hit with US sanctions under Executive Order 13846. The company, which operates in sea and coastal freight transport, was believed to be involved in STS transfers of Iranian oil. It was among more than 30 entities worldwide targeted in the same round of sanctions.
Cision Canada
04-07-2025
- Automotive
- Cision Canada
BIXI launches bike-sharing service in Sherbrooke
SHERBROOKE, QC, July 4, 2025 /CNW/ - BIXI, in collaboration with the Société de transport de Sherbrooke (STS) and the City of Sherbrooke, is proud to announce the launch of the region's first bike-sharing service. The first phase will consist of 25 stations equipped with 255 bikes, 80% of which will be electric. This deployment offers Sherbrooke residents a sustainable, active, and accessible mode of transportation. This project is made possible thanks to a $1,105,581 financial contribution from the Quebec government as part of the Financial Assistance Program for the Development of Self-Service Bike Sharing (OVLIS) for the 2021-2022 fiscal year, a program stemming from the Sustainable Mobility Policy – 2030. At an event held today in Sherbrooke attended by Mayor Évelyne Beaudin, STS Chair Laure Letarte-Lavoie, and other local officials, BIXI officially launched the service. A well-equipped network geared to the region's needs The BIXI Sherbrooke network was designed to meet the specific requirements of the region, with stations strategically located near transportation hubs, educational institutions such as the University of Sherbrooke and Cégep de Sherbrooke, parks, and commercial areas. The number of stations and bikes will increase in the coming years. Users will be able to take advantage of flexible pricing, with monthly subscriptions as well as one-way trips for occasional travel. "I am pleased to see that this bike-sharing service is generating enthusiasm among the public. Our government remains an important partner in ensuring better access to various modes of transportation across all regions of Quebec. The project launched today will have a positive impact on the mobility and quality of life of our citizens in Estrie, which is my goal!" - Geneviève Guilbault, Minister of Transportation and Sustainable Mobility "It is a great pleasure to welcome BIXI to Sherbrooke! This service enhances our sustainable transportation options and makes our downtown even more attractive by facilitating access to businesses, contributing to the local economy. With electric bikes, even our hilly terrain becomes more welcoming! And this is just the beginning, with our cycling network constantly improving to make Sherbrooke even more welcoming for cyclists, both local and from elsewhere." - Évelyne Beaudin, Mayor of Sherbrooke "The rollout of this bike-sharing project fits perfectly with the STS's mission to promote sustainable and integrated mobility in Sherbrooke. By adding bike sharing services to our offering, we are promoting complementary modes of transportation and encouraging Sherbrooke residents to rethink their travel habits, one pedal stroke at a time," said Laure Letarte-Lavoie, President of the STS. "Being part of the large BIXI network means having access to a single app for all cities, enjoying simple pricing and unlimited zone subscriptions. It's connectivity in mobility, at the service of users," said Christian Vermette, General Manager of BIXI. BIXI coming soon throughout Quebec With this new expansion, BIXI is furthering its goal of expanding across Quebec. After Sherbrooke, BIXI is preparing to launch its service in Saint-Eustache, Deux-Montagnes and Saint-Lambert in 2025, bringing the network to a total of 13 partner cities, 12,600 bikes and more than 1,000 stations. Users can now locate stations, rent a bike, and plan their trips via the BIXI mobile app or the BIXI website. About BIXI BIXI Montréal is a non-profit organization responsible for managing bikesharing services in Montréal, Westmount, Mount-Royal, MontréalEst, Longueuil, Laval, Boucherville, Terrebonne, Sainte-Julie and, soon, Sherbrooke, Saint-Eustache, Deux-Montagnes and Saint-Lambert. By 2025, the BIXI network will include 12,600 bicycles, including 3,200 electric bikes, at 1,080 stations in 13 cities. Montreal has the largest fleet of electric bikes in Canada, and one of the largest in North America.
Associated Press
01-07-2025
- Business
- Associated Press
Cole Engineering Awarded $62M U.S. Army Production Contract for Next-Generation Stinger Training System
- CESI is closing the gap in live force-on-force training with innovative Live Training solutions - ORLANDO, Fla., July 1, 2025 (SEND2PRESS NEWSWIRE) — Cole Engineering Services, Inc. (CESI), a By Light Company, has been awarded a $62 million production contract by the U.S. Army's Program Executive Office for Simulation, Training, and Instrumentation (PEO STRI) to deliver more than 100 Stinger Training Systems (STS) over the next five years. This award follows a successful prototyping effort and represents a major step forward in the Army's modernization under the Synthetic Training Environment (STE). STS is a critical component of the STE's Live Training Systems (STE-LTS) Increment 1, designed to close live force-on-force training gaps and deliver scalable multi-domain realism. The STS is part of the CESI Family of Live Training Products, which includes both direct and indirect fire weapons training solutions. Together, these capabilities deliver software-defined, high-fidelity training experiences across a range of operational scenarios, engineered for total situational dominance. 'At the core of our STS solution is CESI's commercial artificial intelligence and computer vision application that revolutionizes optical tracking and engagement fidelity,' said Thomas Fransson, Senior Vice President, Simulation Products & Services at CESI. 'CESI brings battlefield precision to the training range, enabling warfighters to train with greater realism, agility, and trust in their systems.' The STS replicates guided munition effects and integrates seamlessly with current Tactical Engagement Simulation Systems (TESS) and STE instrumentation. These ruggedized, interoperable systems will be fielded across Brigade Combat Teams and Combat Training Centers, enhancing readiness through next-generation realism and reliability. This production award includes system delivery, lifecycle support, and planned integration with future STE-LTS capabilities, reinforcing CESI's commitment to delivering the tip of the spear for modern Air Defense Artillery (ADA) training through AI-enhanced optical targeting. To support STS and other strategic Artificial Intelligence (AI) initiatives, By Light has officially launched AI Lab, an innovation hub designed to accelerate the development, testing, and deployment of AI-enabled solutions across defense, cybersecurity, and enterprise domains. About CESI Cole Engineering Services, Inc. (CESI), a By Light Company, delivers software-defined training, simulation, and cyber solutions that support the integrated multi-domain force. Since 2004, CESI has led the development and integration of Live, Virtual, Constructive, and Gaming (LVCG) environments, serious games, wargaming, and cyber training platforms. CESI delivers open, modular, and scalable solutions that accelerate capability delivery, reduce legacy overhead, and enhance readiness. We equip warfighters with adaptable, outcome-driven technologies to train, fight, and win across contested domains. Learn more at About By Light By Light Professional IT Services LLC is an ISO 9001, 20000-1, and 27001 registered and CMMI-Dev Level 3 rated systems integrator that provides secure turnkey systems by incorporating exceptional engineering, project management, telecommunications, and cyber capabilities to safeguard mission success. Founded by industry professionals with extensive knowledge in DoD, DISA, and other U.S. Government agencies, By Light successfully implements technical solutions that integrate commercial best practices to meet the needs of the government. For more information, visit About the By Light AI Lab By Light's dedicated AI Lab serves as a collaborative center of excellence, integrating advanced machine learning, generative AI, and data analytics into mission-critical systems. With a strong emphasis on ethical AI, trustworthiness, data integrity, real-time threat detection, and automated decision support, the AI Lab enables By Light and its partners to rapidly prototype, validate, and deploy next-generation AI capabilities that advance national security objectives and drive digital transformation. LOGO link for media: NEWS SOURCE: By Light Professional IT Services Keywords: Defense and Military, Cole Engineering Services, Simulation, Training, and Instrumentation, commercial artificial intelligence and computer vision application, By Light Professional IT Services LLC, ORLANDO, Fla. This press release was issued on behalf of the news source (By Light Professional IT Services) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127341 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
30-06-2025
- Business
- Yahoo
Kalmar and AGL collaborate on STS crane repair and refurbishment project in Abidjan
STS crane repair and refurbishment project in Abidjan STS crane repair and refurbishment project in Abidjan KALMAR CORPORATION, TRADE PRESS RELEASE, 30 JUNE 2025 AT 10 AM (EEST) Kalmar and AGL collaborate on STS crane repair and refurbishment project in Abidjan Kalmar and Africa Global Logistics (AGL) have cooperated on a project to refurbish two ship-to-shore (STS) cranes at AGL's container terminal in the Port of Abidjan, Ivory Coast. The project was delivered as part of Kalmar's Modernisation Services offering. The order was booked in Kalmar's Q4 2024 order intake, and the work was completed during Q1 2025. AGL, part of MSC, employs over 20,000 people across 50 countries and is a major player in the port logistics sector in Africa. The company operates 17 container terminals, seven RoRo/ConRo terminals and one inland port terminal and invests in port infrastructure to serve shipowners, import and export customers and the countries in which it operates. AGL's equipment fleet includes Kalmar reachstackers and forklifts. Kalmar has successfully completed several similar repair and refurbishment projects for AGL's crane fleet, including on units operating at the company's terminals in Congo and Benin. The project scope for the cranes in Abidjan included replacement of the cranes' forestay and pivot point bearings, trolley rails, short rails and trolley and guide wheels. Kehinde Salami, Deputy Technical Director, HQ Technical Department, AGL: 'We have collaborated with Kalmar on several crane repair and refurbishment projects in the past, all of which have been completed on time and to the highest standards of quality. It was therefore a natural step to work with them again on the project at Abidjan. The work done by Kalmar will help to keep our STS cranes operating safely and reliably.' Peter Bos, Project Manager, Kalmar: 'We are proud that AGL chose to rely on our deep crane repair and refurbishment expertise for this latest project in Abidjan. In addition to the repair and refurbishment work, we also delivered a comprehensive maintenance training programme for the team of port technicians at Abidjan that will help them ensure the cranes remain in optimal condition far into the future.' Further information for the press: Thomas Malmborg, President, Services, Jenni Laukkonen, Director, Marketing and Communications, Kalmar Services, tel. +358 40 8322 331, Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,200 people. In 2024, the company's sales totalled approximately EUR 1.7 billion. Attachments STS crane repair and refurbishment project in Abidjan STS crane repair and refurbishment project in Abidjan
Business Upturn
24-06-2025
- Health
- Business Upturn
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
Heat-triggered release mechanism unequivocally confirmed Favorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS) One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG 2 -TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). The Phase I study is assessing the safety, pharmacokinetics (PK), and preliminary efficacy of THE001 + RHT in participants with locally advanced unresectable or metastatic STS, who have exhausted all prior treatment options, including standard doxorubicin (DOX). Despite the early stage of development and a small number of participants, signs of meaningful clinical activity have emerged. Among the heavily pre-treated participants – including patients pre-treated with DOX – the median progression-free survival (PFS) following treatment with THE001 + RHT reached 4.5 months across both dose levels (20 and 40 mg/m²). This exceeds the typical median PFS of 2.7 to 3.5 months observed with first-line DOX therapy in treatment-naïve patients at DOX doses of 75 mg/m2, i.e., 2-4x higher than doses of THE001 applied in the Phase I setting. At dose level 2 (40 mg/m²), the mean PFS reached 7.1 months. Two out of three participants in this dose level achieved a partial response (PR) according to Choi criteria and completed the maximum extended treatment phase of 12 cycles (~8.3 months). Notably, one participant whose tumor was initially considered unresectable, could undergo surgical resection at the end of the extended study treatment. This participant showed a tumor shrinkage of -16% in the sum of target lesions, a partial response according to Choi criteria and no vital tumor cells in the resected target lesion. Across dose levels 1 and 2, THE001 + RHT demonstrated a favorable safety profile. There were no dose-limiting toxicities or high-grade treatment-related adverse events that led to treatment discontinuation, underscoring the good tolerability of THE001 in combination with RHT. 'These findings not only provide consistent proof of the galenic concept of heat-triggered, largely complete DOX release from THE001, but also demonstrate clinical benefit in a highly challenging patient population,' said Dr. Frank Hermann, Chief Medical Officer of Thermosome. 'We are particularly encouraged by the results of one participant who underwent resection after 12 full treatment cycles with THE001 and regional hyperthermia with no vital tumor cells found in the resected target lesion. These results clearly support future exploration in the neoadjuvant setting.' Alexander Eggermont, Professor of Clinical and Translational Immunotherapy, University Medical Center, Utrecht, and a member of Thermosome´s Clinical Advisory Board, commented: 'The Phase I data of THE001, a thermosensitive liposomal DOX, and regional hyperthermia in heavily pre-treated DOX-experienced soft tissue sarcoma patients, particularly from dose level 2, are very encouraging. These results demonstrate the clinical potential of this highly innovative approach and provide the necessary foundation for transitioning into Phase II proof-of-concept development. I am excited to support this important work and look forward to advancing this promising therapy, which has the potential to significantly improve outcomes for patients with soft tissue sarcoma, particularly in the neoadjuvant setting.' 'It is exciting to see the promising results of THE001 combined with regional hyperthermia, demonstrating strong potential to address the high unmet need for better treatments for soft tissue sarcoma,' added Prof. Shreyaskumar Patel, the Robert R. Herring Distinguished Professor of Medicine and Medical Director of the Sarcoma Center at The University of Texas MD Anderson Cancer Center, Houston Texas, and a member of Thermosome's Clinical Advisory Board. 'Expansion into Phase II, also including the U.S., would offer a much-needed validation of this new therapeutic strategy for patients with STS. I look forward to supporting the advancement of this innovative treatment option to improve outcomes for patients here in the U.S. and globally on the back of the orphan drug designation granted by the FDA.' Considering supportive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) on the development of THE001 + RHT in the neoadjuvant setting, the available data from last-line participants are intended to support further development in the neoadjuvant setting. ### About Thermosome Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentration and improved tumor penetration to achieve improved clinical treatment efficacy. The first clinical indication for its lead drug candidate THE001 is soft tissue sarcoma, where the Company aims to improve the current standard of care (free doxorubicin). Thermosome's approach enables targeted tumor treatment independent of specific molecular targets and covers patient populations across all chemo-sensitive tumor subtypes. More information: About THE001 Thermosome's clinical-stage lead drug candidate THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG 2 -TSL-DOX). It has a different mode of action than conventional liposomes. Thermosome's technology enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentrations in the tumor and aims to improve clinical treatment efficacy by creating a local boost at the desired site of action. These high local concentrations, which also reach less well perfused areas, are intended to overcome drug resistance. This effect cannot be achieved by administration of conventional doxorubicin due to systemic toxicity. Thermosome intends to further enhance treatment efficacy through an additive immune response induced by regional hyperthermia. THE001 has potential for further development in other anthracycline-sensitive solid tumors, such as breast, bladder, and ovarian cancer. THE001 has been granted Orphan Drug Designation for STS in Europe and the United States. About the Phase I Study The Phase I, open-label, interventional dose-escalation trial enrolling patients with (including DOX-) pre-treated locally advanced unresectable or metastatic STS (NCT05858710) is being conducted at two German clinical sites testing THE001 at various different dose levels in initially up to 6 cycles every 3 weeks with option to extend to up to 12 cycles in participants with at least disease control. Both completed dose level (20 mg/m² and 40 mg/m²) were well tolerated and declared safe by the independent data safety monitoring board (DSMB). Primary endpoints of the study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is the evaluation of anti-tumor activity. Initial clinical data were presented at the CTOS 2024 Annual Meeting (link). About Soft Tissue Sarcomas (STS) STS is an atypical tumor with a patient population that includes many young patients. Locally advanced STS (LA-STS) are large invasive tumors that are difficult or impossible to resect. Neoadjuvant therapy is used to shrink these tumors preoperatively to allow tumor surgery with curative intent. Free doxorubicin in combination with ifosfamide or dacarbazine has been the gold standard for neoadjuvant therapy of all chemo-sensitive LA-STS for several decades. Guidelines also recommend combining DOX-based therapy with regional hyperthermia. However, with response rates of less than 30%, there is a significant unmet need for improved treatment options. Soft tissue sarcomas occur in more than 50 different subtypes that do not share a common driver mutation, making biologic targeting more difficult than physically controlled targeting with the most active agent. Company ContactThermosome GmbHAm Klopferspitz 1982152 Planegg/Martinsried (Germany)Phone: +49 89 7167760 31 [email protected]
